Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study

Maria Rosaria Valerio, Vittorio Gebbia, Gabriella Moretti, Mariangela Ciccarese, Luca Clivio, Nicla La Verde, Mirco Pistelli, Vittorio Gebbia, Alessandra Fabi, Donata Sartori, Antonella Ferzi, Francesco Atzori, Cristina Ancona, Maria Concetta Cursano, Chiara Benedetto, Ornella Garrone, Marina Cazzaniga, Alberto Fumagalli, Lucrezia Diodati, On Behalf Of The Eva Study GroupMatilde Piezzo, Antonio Schirone, Valentina Arcangeli, Mario Airoldi, Anna Turletti, Nicla La Verde, Donata Sartori, Valentina Arcangeli, Antonio Schirone, Claudio Scavelli, Daniele Generali, Michela Maur, Salvatore Artale, Livio Blasi, Antonio Febbraro, Claudio Verusio, Antonio Frassoldati, Patrizia Vici, Corrado Ficorella, Alberto Zambelli, Maria Rosaria Valerio, Antonino Musolino, Valter Torri, Raffaella Palumbo, Giulia Bianchi, Lucia Mentuccia

Risultato della ricerca: Articlepeer review

2 Citazioni (Scopus)

Abstract

BACKGROUND: The present analysis focuses on real-world data of Everolimus- Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years. METHODS: Data are collected from clinical records and analysed according to age cut-off (< 65 years; 65 - 69 years and [greater than or equal to] 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel- Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model. RESULTS: From July 2013 to December 2015, the EVA study enrolled overall 404 pts. 154 patients out of 404 (38,1%) were aged [greater than or equal to] 65 years, of whom 87 were [greater than or equal to] 70 years. Median duration of EVE treatment was 28.5 weeks (95% CI 19.0 - 33.8) in patients aged 65-69 years and 24,4 weeks (95% CI 19,2 - 33,2) in those aged [greater than or equal to] 70 years. Fewer patients aged 65 years received the highest EVE Dose-Intensity (> 7.5 mg/day) in comparison to younger patients (49,6% vs. 66,8%). Grade 3-4 toxicities occurred to 55 patients (35,7%), mainly stomatitis (10,9%), rash (5,8%) and non-infectious pneumonitis (NIP) (3,6%). Some toxicities, such as weight loss and anaemia were peculiarly observed in patients aged [greater than or equal to] 70 years. Five treatment-related deaths were collected (3,2%). CONCLUSIONS: EVE-EXE combination remains one of the potential treatments in HR+ patients also for elderly ones.
Lingua originaleEnglish
pagine (da-a)31877-31887
Numero di pagine11
RivistaOncotarget
Volume9
Stato di pubblicazionePublished - 2018

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2730???

Fingerprint

Entra nei temi di ricerca di 'Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study'. Insieme formano una fingerprint unica.

Cita questo